Business

NeuroMetrix begins marketing launch of a diabetes diagnostic product in Japan

Photo taken from the company’s website.

NeuroMetrix Inc., a Waltham company whose product portfolio includes diagnostics for diabetes, announced the marketing launch of one of its products in Japan.

The product is called NC-stat DPNCheck, and it is designed to detect diabetic peripheral neuropathy, or DPN, at an early stage. DPN is the most common complication of diabetes, affecting more than half the diabetes population, the company’s press release noted. Diabetes is a major health issue in Japan affecting nearly 8 percent of the population, or about 7 million people.

Advertisement

Omron Healthcare, a company based in Kyoto, Japan, that specializes in health care monitoring, is NeuroMetrix’s exclusive distributor for Japan and other Asian markets. Omron is currently guiding DPNCheck through the Japan regulatory process which is expected to conclude during this quarter, NeuroMetrix said.

The annual meeting of the Japan Diabetes Society is scheduled to run from Thursday through Saturday. The plan is to use this event to unveil a product awareness campaign for the DPNCheck, the company said.

Get Talking Points in your inbox:
An afternoon recap of the day’s most important business news, delivered weekdays.
Thank you for signing up! Sign up for more newsletters here

According to the NeuroMetrix website, the company’s product portfolio includes “wearable medical technology and point-of-care diagnostics that help patients and physicians better manage chronic pain, nerve disorders, and associated sleep disturbances.”

The company was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996 by Shai Gozani, MD, NeuroMetrix’s president and chief executive.

Chris Reidy can be reached at reidy@globe.com.
Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.